Renaissance Technologies LLC Decreases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Renaissance Technologies LLC trimmed its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 71.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,900 shares of the company’s stock after selling 123,000 shares during the period. Renaissance Technologies LLC’s holdings in Sana Biotechnology were worth $272,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Sana Biotechnology by 86.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 42,400 shares of the company’s stock valued at $424,000 after acquiring an additional 19,600 shares in the last quarter. Hartline Investment Corp acquired a new stake in Sana Biotechnology during the 1st quarter valued at approximately $136,000. Baillie Gifford & Co. increased its holdings in Sana Biotechnology by 5.0% during the 1st quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock worth $106,563,000 after purchasing an additional 506,262 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Sana Biotechnology in the 1st quarter valued at approximately $1,343,000. Finally, ProShare Advisors LLC boosted its stake in shares of Sana Biotechnology by 14.8% during the 1st quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock valued at $327,000 after buying an additional 4,210 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of research analyst reports. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research note on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price target for the company. Citigroup upped their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright decreased their price target on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, August 9th.

Insider Activity

In related news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the sale, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 31.10% of the company’s stock.

Sana Biotechnology Price Performance

SANA stock opened at $3.99 on Friday. The firm has a market cap of $883.80 million, a price-to-earnings ratio of -2.61 and a beta of 1.42. Sana Biotechnology, Inc. has a 1-year low of $2.74 and a 1-year high of $12.00. The firm has a fifty day moving average price of $4.81 and a two-hundred day moving average price of $6.51.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). As a group, analysts expect that Sana Biotechnology, Inc. will post -1.13 EPS for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.